Company Overview - Basilea Pharmaceutica Ltd is a commercial-stage biopharmaceutical company based in Allschwil, Switzerland, focused on developing innovative drugs for severe bacterial and fungal infections [7] - The company has successfully launched two hospital brands: Cresemba for invasive fungal infections and Zevtera for bacterial infections [7] Funding and Development - Basilea has received a total non-dilutive funding commitment of up to USD 159 million, which includes an initial amount of USD 6 million, contingent upon meeting predefined milestones [1][2] - The funding is part of a contract novation from Venatorx Pharmaceuticals to Basilea, aimed at supporting the development of the novel oral antibiotic ceftibuten-ledaborbactam etzadroxil for complicated urinary tract infections (cUTIs) [1][2] Product Information - Ceftibuten-ledaborbactam etzadroxil is a beta-lactam/beta-lactamase inhibitor combination designed to treat cUTIs, including pyelonephritis, particularly those caused by multidrug-resistant Gram-negative bacteria [1][4] - The drug has received Qualified Infectious Disease Product (QIDP) and Fast Track designations from the US FDA for cUTI and uncomplicated urinary tract infections [4] Market Need - There is a significant unmet need for effective oral treatments for cUTIs caused by multidrug-resistant bacteria, as current options are limited [6] - Complicated UTIs, including pyelonephritis, are among the most common bacterial infections in both hospital and community settings [5]